Cervical microbiota dysbiosis associated with high-risk Human Papillomavirus infection

PLoS One. 2024 Apr 26;19(4):e0302270. doi: 10.1371/journal.pone.0302270. eCollection 2024.

Abstract

High-risk Human Papillomavirus (HR-HPV) genotypes, specifically HPV16 and HPV18, pose a significant risk for the development of cervical intraepithelial neoplasia and cervical cancer. In the multifaceted cervical microenvironment, consisting of immune cells and diverse microbiota, Lactobacillus emerges as a pivotal factor, wielding significant influence in both stabilizing and disrupting the microbiome of the reproductive tract. To analyze the distinction between the cervical microbiota and Lactobacillus-dominant/non-dominant status of HR-HPV and non-infected healthy women, sixty-nine cervical swab samples were analyzed, included 44 with HR-HPV infection and healthy controls. All samples were recruited from Human Papillomavirus-based cervical cancer screening program and subjected to 16s rRNA sequencing analysis. Alpha and beta diversity analyses reveal no significant differences in the cervical microbiota of HR-HPV-infected women, including 16 and 18 HPV genotypes, and those with squamous intraepithelial lesion (SIL), compared to a control group. In this study we identified significantly lower abundance of Lactobacillus mucosae in women with HR-HPV infection compared to the control group. Furthermore, changes in bacterial diversity were noted in Lactobacillus non-dominant (LND) samples compared to Lactobacillus-dominant (LD) in both HR-HPV-infected and control groups. LND samples in HR-HPV-infected women exhibited a cervical dysbiotic state, characterized by Lactobacillus deficiency. In turn, the LD HR-HPV group showed an overrepresentation of Lactobacillus helveticus. In summary, our study highlighted the distinctive roles of L. mucosae and L. helveticus in HR-HPV infections, signaling a need for further research to demonstrate potential clinical implications of cervical microbiota dysbiosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Case-Control Studies
  • Cervix Uteri* / microbiology
  • Cervix Uteri* / virology
  • Dysbiosis* / microbiology
  • Dysbiosis* / virology
  • Female
  • Human papillomavirus 16 / genetics
  • Human papillomavirus 16 / isolation & purification
  • Human papillomavirus 18 / genetics
  • Human papillomavirus 18 / isolation & purification
  • Humans
  • Lactobacillus* / genetics
  • Lactobacillus* / isolation & purification
  • Microbiota*
  • Middle Aged
  • Papillomavirus Infections* / complications
  • Papillomavirus Infections* / microbiology
  • Papillomavirus Infections* / virology
  • RNA, Ribosomal, 16S* / genetics
  • Uterine Cervical Dysplasia / microbiology
  • Uterine Cervical Dysplasia / virology
  • Uterine Cervical Neoplasms / microbiology
  • Uterine Cervical Neoplasms / virology

Substances

  • RNA, Ribosomal, 16S

Grants and funding

This work was supported by 501-1-009-12-21/MG2 (N.Z-L) grant from the Centre of Postgraduate Medical Education (www.cmkp.edu.pl), 2017/27/B/NZ5/01504 (J.O.) from National Science Centre (www.ncn.gov.pl) and SN/GW/22/2020 (E.W-L.) form Maria Sklodowska-Curie National Research Institute of Oncology (https://nio.gov.pl). Sponsors or funders did not play any role in the design of the study, data collection and analysis, decision to publish or preparation of the manuscript.